Hydroxychloroquine and Chloroquine were part of the four drugs being studied by the WHO in their solidarity trial taking place in over 17 countries. The other drugs were remedesvir and Lopinavir.
The World Health Organisation has halted the use of Hydroxychloroquine in its solidarity drug trial after an observational study published in The Lancet found the drugs to be ineffective in treating the Coronavirus (COVID-19).
Hydroxychloroquine and Chloroquine were part of the four drugs being
studied by the WHO in their solidarity trial taking place in over 17
countries. The other drugs were remedesvir and Lopinavir.
But according to the authors of the largest study on the drugs, published last week, it was discovered that patients who used Hydroxychloroquine alone or in a combination of an antibiotic had higher mortality rates and heart problems than those who were not.
Dr Tedros Adhanom Ghebreyesus, the WHO Director-General says that they have decided to halt the use of hydroxychloroquine arm of its solidarity global clinical trial as a review of evidence on the drugs takes place.
“The executive group has implemented a temporary pause of
the hydroxychloroquine arm within the solidarity trial while the safety data is
reviewed by the data safety monitoring board,” Dr Tedros said. he added that the review will consider data collected so far in the Solidarity Trial
and in particular robust randomised available data, to adequately
evaluate the potential benefits and harms from this drug.
Dr Ghebreyesus, however, added that the two drugs can be used for autoimmune disease or malaria as the review takes place.
Uganda is still using Hydroxychloroquine to treat COVID-19 in its hospitals. According to Dr Diana Atwine, the drug has presented good results in patients that have used it. So far, Uganda had a confirmed 222 COVID-19 patients. 69 of these have already been discharged after testing negative for the virus in subsequent tests.